-The Economic Times MUMBAI: A drug maker found overcharging will have to shell out the entire sales revenue of the medicine from the date of its launch as penalty, according to a directive issued by the country's drug price regulator. "If a company has not been booked for overcharging for selling the product without price approval, if any, pertaining to the period prior to fixation of the price of the said formulation,...

-Live Mint There are also ways in which we can help Indian institutions that have come to us seeking access to our technologies Bangalore: A key perception change is emerging in the global pharmaceutical industry on the long-established divide between the so-called generics and innovative business. While the two are still at loggerheads in several developed as well as developing markets, the world’s top drugmakers are reinventing the wheel. Paris-based Sanofi SA,...

-The Times of India The Centre on Thursday promised to notify a new drug pricing mechanism for essential medicines by the end of November, but the Supreme Court said a change in policy must not force a sharp rise in drug prices to hurt an already hassled common man. Additional solicitor general Siddharth Luthra informed a bench of Justices G S Singhvi and S J Mukhopadhaya that a Cabinet note on the...

-Live Mint Incidents at Bhopal and Indore highlight irregularities and ethical violations in some trials In 2004, doctors at the Bhopal Memorial Hospital and Research Centre (BMHRC), established exclusively for treating the victims of the 1984 gas leak, recruited unsuspecting survivors for clinical trials without their knowledge or consent; 14 participants died during the course of the trials. Together with the episode in Indore’s Maharaja Yashwantrao Hospital (that Mint reported on 10...

-Live Mint The first in a two-part series examining the opaque world of clinical trials in India  A hospital in Indore has been able to get away with unethical medical trials in which 32 people have died over five years, according to the state government. This despite several investigations, a state government ban and Supreme Court strictures—a classic example of the lawless nature of the clinical trial business in India.   Lata Mehra, who...